Itvisma (onasemnogene abeparvovec-brve) Coverage for Spinal Muscular Atrophy
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy CSPA2026D0142B alerts
Get alerted when Policy CSPA2026D0142B changes without checking for updates manually.
Monitor payer policy activity
This medical benefit drug policy governs prior authorization and coverage of Itvisma for treatment of spinal muscular atrophy in Pennsylvania for eligible patients age 2 years and older who meet the policy's genetic, clinical, administration, and treatment-history requirements.
The coverage criterion regarding concomitant SMN-modifying therapy was revised to require that the patient not receive routine concomitant therapy, with medical-record review, without stating that current authorizations will be terminated upon Itvisma approval.
The coverage criterion concerning routine concomitant SMN-modifying therapy was revised.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.